122 related articles for article (PubMed ID: 28079213)
1. A computational mechanistic investigation into the reduction of Pt(iv) prodrugs with two axial chlorides by biological reductants.
Ejehi Z; Ariafard A
Chem Commun (Camb); 2017 Jan; 53(8):1413-1416. PubMed ID: 28079213
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by l-Ascorbic Acid.
Dabbish E; Ponte F; Russo N; Sicilia E
Inorg Chem; 2019 Mar; 58(6):3851-3860. PubMed ID: 30843385
[TBL] [Abstract][Full Text] [Related]
3. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.
Sinisi M; Intini FP; Natile G
Inorg Chem; 2012 Sep; 51(18):9694-704. PubMed ID: 22921246
[TBL] [Abstract][Full Text] [Related]
4. Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.
Zhang JZ; Wexselblatt E; Hambley TW; Gibson D
Chem Commun (Camb); 2012 Jan; 48(6):847-9. PubMed ID: 22124352
[TBL] [Abstract][Full Text] [Related]
5. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.
Chen CK; Zhang JZ; Aitken JB; Hambley TW
J Med Chem; 2013 Nov; 56(21):8757-64. PubMed ID: 24107138
[TBL] [Abstract][Full Text] [Related]
6. New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.
Nemirovski A; Vinograd I; Takrouri K; Mijovilovich A; Rompel A; Gibson D
Chem Commun (Camb); 2010 Mar; 46(11):1842-4. PubMed ID: 20198227
[TBL] [Abstract][Full Text] [Related]
7. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
9. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
Medrano MÁ; Álvarez-Valdés A; Perles J; Lloret-Fillol J; Muñoz-Galván S; Carnero A; Navarro-Ranninger C; Quiroga AG
Chem Commun (Camb); 2013 May; 49(42):4806-8. PubMed ID: 23591566
[TBL] [Abstract][Full Text] [Related]
10. Reduction of a platinum(iv) prodrug model by sulfur containing biological reductants: computational mechanistic elucidation.
Chipman A; Yates BF; Canty AJ; Ariafard A
Chem Commun (Camb); 2018 Sep; 54(74):10491-10494. PubMed ID: 30159577
[TBL] [Abstract][Full Text] [Related]
11. Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.
Savino S; Gandin V; Hoeschele JD; Marzano C; Natile G; Margiotta N
Dalton Trans; 2018 May; 47(21):7144-7158. PubMed ID: 29766157
[TBL] [Abstract][Full Text] [Related]
12. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.
Varbanov HP; Valiahdi SM; Kowol CR; Jakupec MA; Galanski MS; Keppler BK
Dalton Trans; 2012 Dec; 41(47):14404-14415. PubMed ID: 22886297
[TBL] [Abstract][Full Text] [Related]
13. Platinum(IV) Prodrugs.
Venkatesh V; Sadler PJ
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
[TBL] [Abstract][Full Text] [Related]
14. Reduction of ormaplatin by an extended series of thiols unravels a remarkable correlation.
Dong J; Tian H; Song C; Shi T; Elding LI
Dalton Trans; 2018 Apr; 47(16):5548-5552. PubMed ID: 29611592
[TBL] [Abstract][Full Text] [Related]
15. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
Cubo L; Hambley TW; Sanz Miguel PJ; Carnero A; Navarro-Ranninger C; Quiroga AG
Dalton Trans; 2011 Jan; 40(2):344-7. PubMed ID: 20936210
[TBL] [Abstract][Full Text] [Related]
16. Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs.
Johnstone TC; Alexander SM; Wilson JJ; Lippard SJ
Dalton Trans; 2015 Jan; 44(1):119-29. PubMed ID: 25367395
[TBL] [Abstract][Full Text] [Related]
17. A multi-methodological inquiry of the behavior of cisplatin-based Pt(IV) derivatives in the presence of bioreductants with a focus on the isolated encounter complexes.
Corinti D; Crestoni ME; Fornarini S; Dabbish E; Sicilia E; Gabano E; Perin E; Osella D
J Biol Inorg Chem; 2020 Jun; 25(4):655-670. PubMed ID: 32296997
[TBL] [Abstract][Full Text] [Related]
18. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
[TBL] [Abstract][Full Text] [Related]
19. Understanding intrinsically irreversible, non-Nernstian, two-electron redox processes: a combined experimental and computational study of the electrochemical activation of platinum(IV) antitumor prodrugs.
McCormick MC; Keijzer K; Polavarapu A; Schultz FA; Baik MH
J Am Chem Soc; 2014 Jun; 136(25):8992-9000. PubMed ID: 24853204
[TBL] [Abstract][Full Text] [Related]
20. Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions.
Wexselblatt E; Yavin E; Gibson D
Angew Chem Int Ed Engl; 2013 Jun; 52(23):6059-62. PubMed ID: 23686723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
